Methemoglobinemia (StatPearls review chapter) (2025)

Peer-Reviewed Study · Richard Chen; Thomas Nappe (StatPearls Publishing) · December 14, 2025

Richard Chen et al., 2025-12-14: Current clinical review chapter that distinguishes the congenital cytochrome b5 reductase (CYB5R) forms of methemoglobinemia from acquired forms and states what to suspect when methylene blue fails.

If methylene blue administration is ineffective after a 2nd dose, underlying conditions, such as, but not limited to, G6PD deficiency and NADPH-MetHb reductase deficiency, should be considered as potential causes of treatment refractoriness.

Richard Chen et al., 2025-12-14: Current clinical review chapter that distinguishes the congenital cytochrome b5 reductase (CYB5R) forms of methemoglobinemia from acquired forms and states what to suspect when methylene blue fails. C4 and C3. Study type: narrative review / continuing-education chapter, no patients. States type I CYB5R defects are confined to erythrocytes while type II affects all cell types; recommends methylene blue 1-2 mg/kg (0.1-0.2 mL/kg of 1% solution) IV over 5 minutes, repeated after 30-60 minutes if needed; notes G6PD deficiency is a caution rather than an absolute contraindication and that hemolysis has been observed above 5 mg/kg; alternatives are ascorbic acid, exchange transfusion and hyperbaric oxygen. Authors' disclosures: Richard Chen and Thomas Nappe declare no relevant financial relationships with ineligible companies. Quote verified against the Bookshelf HTML retrieved with the web_extract route (the plain HTTP fetch is served a reCAPTCHA stub). Study type: review.